Howdy, Stranger!

It looks like you're new here. If you want to get involved, click one of these buttons!

Here's a statement of the obvious: The opinions expressed here are those of the participants, not those of the Mutual Fund Observer. We cannot vouch for the accuracy or appropriateness of any of it, though we do encourage civility and good humor.
  • Express Scripts, AbbVie & Gilead
    FWIW, a relative took the injections about 5 years ago for Hep C. Super lucky to have very few side effects. All new oral drugs are much better. If patient is not suitable for Abbvie, doctor can request Harvoni. Best wishes for the uncle.
  • Express Scripts, AbbVie & Gilead
    My husband takes a on-patent name brand drug. The generic in-class alternative is a drug with dangerous metabolites and requires restricted diet. No plan should be able to substitute a generic (or cheaper) alternative when the active ingredient is a different chemical even if it is in-class. Express Scripts under my plan allowed for the safer drug.
    Because I am currently using Express Scripts (go to Caremark in a few days) I searched for Harvoni under my plan. It said that it was covered but might require a coverage review. It said that Harvoni was not the preferred drug but when I asked for a "generic alternative' it said there was none.
    My plan pays 90% of the cost of a name brand and has a limit on my cost. I've never seen the "coverage review" message but it might just be related to a new prescription of this sort going in a few days before the account moves to a competitor. I was unable to get it to show me the preferred alternatives.
    Here is the price Express Scripts gave me for a 30 day supply:
    Total cost: $30,423.75
    Your cost for this medication: $116.66
    What your plan pays for this medication*: $30,307.09
    Your plan pays approximately 100% of the cost for this medication.
    *The cost to your plan does not include any rebates or other incentives your plan may receive from your use of this medication. Express Scripts may retain or share some rebates with your plan. The cost your plan pays is an approximation and is subject to change.
    Coverage alert
    Coverage Review is required for Harvoni 90-400 Mg Tablet.
    For Participating Retail Pharmacy: This drug requires Coverage Review before you can receive it.
    For Home Delivery Pharmacy: This drug requires Coverage Review before you can receive it.
    More about coverage reviews:
    To receive coverage for this medication, you must obtain approval through a coverage review. If you do not do this, you may be responsible for the entire cost of the medication.
    Coverage notes
    For Harvoni 90-400 Mg Tablet when using your home delivery pharmacy benefit:Please wait ...
    This medication is covered under your plan; however, it is a non-preferred product.
    Please note that the coverage terms of this prescription benefit are subject to change.
  • An Emerging Retirement Drawdown Controversy
    Hi Guys,
    Charles’ recent “Irrational Markets - Proof Positive” post prompted me to initiate this topic. That discussion highlighted the discordant opinions and recommendations made by supposedly financial and investment experts. The cacophony is loud, endless, and often much less than useful. Chaotic investing is a likely outcome.
    The Charles post emphasized the mind-bending character of old wisdom saws like “Out of the mouths of babes comes wise insights, yet, only with age comes wisdom”.
    If the latter is true, I have accumulated much wisdom. I guess you should seek investment advice from either young Wharton business school graduates or perhaps from older, more senior graduates. I listen to both, but weight them differently.
    For many years, an industry agreement seemed to have been reached with regard to an acceptable retirement portfolio drawdown rate. Portfolio survival for an extended retirement period is the obvious goal.
    These earlier studies mostly suggested something approaching a 50/50 mix of equity and fixed income holdings. High portfolio survival rates were estimated when withdrawal rates were limited to roughly 4% per year adjusted for inflation. The original work in this arena was done at Trinity University in 1998 and has been frequently updated.
    Here is a Link to one readable update written by Wade Pfau in 2010:
    http://wpfau.blogspot.com/2010/10/trinity-study-retirement-withdrawal.html
    The Pfau analysis didn’t much change the earlier study findings. However, some concern over the current overpriced marketplace, coupled with a very low interest rate environment, has persuaded a few gurus to shorten the recommended drawdown schedule from the standard 4% rule-of-thumb to an even lower 3% annually.
    Now for the controversial analysis and recommendation that wants to upset this comfortable apple cart. It will surely add to Charles’ distress over conflicting and competing financial advice. That’ll never change.
    It is a retirement study from the Director of Research at the Putnam Institute. Here is the Link to this cart upsetting 16-page, 2011 release:
    https://www.putnam.com/literature/pdf/PI001.pdf
    Please give it a road test. It merges portfolio returns uncertainty with life expectancy probabilities for both men and women separately. The methodology deploys a novel Retirement Present Value (RPV) model to project portfolio survival likelihoods.
    The RPV’s surprising and controversial output is that the retirement portfolio that offers the best survival prospects includes a much smaller fraction of equity holdings than does the original Trinity study and other follow-up Monte Carlo analyses. Check it out; controversy is good.
    Personally, I’m not comfortable with the Putnam work product. The manner in which the “optimum” portfolio equity/fixed income mix was determined escapes me. Certainly a portfolio with only a single Index-like equity position is retirement dangerous because of its volatility (standard deviation). But fixed income is likely more dangerous because of muted annual returns.
    The standing answer has been broad portfolio diversification that trades off a little annual return for a major decrease in overall volatility. Outcomes are definitely timeframe dependent, but I still trust this generic and time-tested approach.
    You get to choose your own poison. My head spins off-axis as often as Charles’ does. Let MFO members know your thinking on this matter.
    Best Regards and Happy Holidays.
  • Is It Time to Throttle Back Equities?
    OK - I guess I was wrong about market timing.
    2 Timothy 3:1-5 ESV
    But understand this, that in the last days there will come times of difficulty. For people will be lovers of self, lovers of money, proud, arrogant, abusive, disobedient to their parents, ungrateful, unholy, heartless, unappeasable, slanderous, without self-control, brutal, not loving good, treacherous, reckless, swollen with conceit, lovers of pleasure rather than lovers of God, having the appearance of godliness, but denying its power. Avoid such people.
    2 Corinthians 11:14 ESV
    And no wonder, for even Satan disguises himself as an angel of light
  • Express Scripts, AbbVie & Gilead
    I know this site is dedicated to funds/etf's, but the captioned story affects many due to the high institutional ownership of biotech companies such as AbbVie and Gilead Sciences.
    An uncle of mine was due to start using Gilead Sciences Harvoni regimen to cure his Hepatitis C beginning January 5, 2015. Because Express Scripts is his pharmacy benefit provider, my uncle now must change his prescription from the 1 pill a day Harvoni to AbbVie's drug cocktail to cure his Hep. C. This is what his doctor has told him. My uncle has yet to receive any reply from Express Scripts to his many inquiries!!!!!
    I understand the high cost issue of using Gilead's Harvoni, although AbbVie's new Hep. C cocktail is still very costly. Nonetheless I (and my family) feel that my uncle's physician should be the person determining my uncle's medication, not the pharmacy benefit provider (Express Scripts). It's not fair to any human being that their medication is determined by a pharmacy benefit provider instead of a capable physician as we want only the best health care for my uncle.
    I see that neither Gilead nor AbbVie's pps are up today, although Gilead really took a hit while Express Scripts is up on this news. I don't directly own any of these equities but do own them through some funds, and am simply angry at Express Scripts on my uncle's behalf.
    Just needed to get this off of my chest.
    ~ PT
  • In Defense Of Advisors Who Sell Variable Annuities
    I trust that you don't advise Monument (Jeff Nat) policy holders to annuitize. That would convert the segregated account assets into general liabilities of the insurance company ("subject to the claims-paying ability of the insurer"), currently rated B+ by A.M. Best, C by Weiss, and unrated by anyone else. Not to mention its heritage (Conseco), and the fact that the product is not offered in NY State.
    Aside from Conseco being one of the largest bankruptcies ever, it let hedge funds use the Monument VA for market timing from around 1999-2002. Then it sold off its annuity unit to Jefferson National, who continued the market timing practices (fraudulently stating in its prospectus that the annuity was not intended for market timing). That ran from Oct 2002 (when Jefferson National acquired the unit) through Sept 2003. Here's the SEC settlement.
    None of this is intended to imply that I would not personally consider the Monument Annuity - but that I would know exactly what I was getting into - mostly in terms of insurer risk.
    I am glad to see you list other low cost VAs, which can (in limited circumstances, for the right customers) serve a role. To the others you'd mentioned, I would add TIAA-CREF (the only low cost annuity I know of sold in NYS without fudging via a separate subsidiary), and Fidelity.
  • Is It Time to Throttle Back Equities?
    I have no issue with people who have all manner of strategies. I'm a believer in "do what works for you."
    Personally, I've turned into much more of a "buy and hold" investor in the last few years from the standpoint of it's just not very enjoyable to me to have to frequently rebalance and tweak.
    There may be some variation in the desired holding periods for me, ranging from multi-decade (railroads fall within this, as well as some other things including Archer Daniels, International Flavors and Fragrances and Jardine Matheson), to 5-10 year (Ecolab, Visa, WP Carey as examples) and a lot that I have a 3-5 view on.
    Things change, absolutely, but I think the Buffett quote of "Buy what you would feel comfortable with if the market closed for 10 years" is a good filter in the decision making process.
  • WHAT COLUMBUS MISSED: Royce Rediscovers India:
    MINDX has performed well over this year, but as @JohnChisum mentioned India funds have had a history of providing a roller coaster of a ride. This past year, MINDX has exhibited very little volatility as well as consistent upward momentum. As @Junkster has mentioned of his investment choices, MINDX has exhibited a movement over the past year that I believe he would call "strong upward momentum with very little volatility".
    I like to use MAPIX as my "safe harbor" (diversified fund for Asia exposure) so I chart MINDX against MAPIX to determine MINDX relative volatility. Over the last year MAPIX has moved sideways while MINDX provided a 60% gain.
    image
    I am watching shorter charts of 1 & 3 months for higher volatility signals again using MAPIX as my indicator. The most recent 1 month chart indicates pretty similar movement compared to MAPIX.
    image
  • In Defense Of Advisors Who Sell Variable Annuities
    Fortunately a very tongue-in-cheek essay. Quite clever, actually.
    We have had a number of clients who come to us with existing variable annuity contracts. If they are lucky, they have held them long enough to be free of deferred sales charges. Some have come in with 10-year surrender/deferred charges, some owned by folks who are in their 70s and 80s (yeah, real ethical salespersons). If there is no net gain, the contracts can be surrendered. If there is a gain of any size, at least they can be 1035-exchanged to a no-load product (like Jefferson National, Vanguard, or Schwab). Sadly, most are sold by bank salespersons, who know almost nothing about the products they sell, except that they are told to push them. The annual expenses can really be awful, not to mention the salespersons almost never disclose that owners can only access 10% of the principal in the first year. All who have been sold these products think otherwise.
    There may be honest, ethical variable annuity salespersons out there somewhere.
  • The Various Flavors of Long Short Equity Funds.
    GENIX has been open less than 2 years (since May 31, 2013). Classic pattern for many of these boutique funds with high fees. Tailor a hot combination of investments (in this case 99.5% equities) and ride the wave. Watch the money pour in (already over 1.5 BL). Pump that new money into the currently hot sectors. A year (or two or three) later, the market climate changes and the fund starts to swoon. The money pours out as fast as it came in and everybody is convinced the fund's losses are attributable to "bloat" (missing the larger issue).
    As usual, those who were last in and last to leave suffer the losses.
    Seen this over and over with these funds.
  • The Various Flavors of Long Short Equity Funds.
    Most have struggled this year, as the article mentions...one of my favorites WBMIX is off 3.5% YTD. Honestly, hard to beat the pure index in this market.
    I don't think the article mentioned a different kind of long/short strategy that is doing well lately...Gotham Absolute Return Fund (GARIX)...up 9% YTD, or Gotham Enhanced Return Fund (GENIX)...up 16.7% YTD. I'm actually reluctant to call attention to Gotham's Funds, despite my admiration for Mr. Greenblatt...hard for me to get past the 2.25% er. But, in this case, so far anyway, must give these funds credit.
  • Target-Date Funds: Twice As Popular Vs. 15 Years Ago
    Note:
    For some reason, Ted's link to his original article disappeared or became inoperative after I wrote a response. Not good. Here's the original article to which I was responding:
    http://www.nasdaq.com/article/target-date-funds-twice-as-popular-vs-15-years-ago-cm425440
    The comparison is with 1998. That was an extraordinarily "euphoric" period for retail investors for many reasons. So, the rise in popularity of balanced funds in subsequent years doesn't surprise me.
    If I'm reading this article correctly, it's really about balanced funds "which include target-date funds" (quoting from article). I find this presentation a bit suspicious.
    That aside, it's unfortunate so called "target date" funds get lumped together at all by financial commentators like this one. They vary greatly in their approach to investing. If you want a good one, look to the fund family first. That's where it all starts with these things.
  • BlackRock Continues To Make The Most Of The ETF Growth Story
    FYI: The exchange-traded fund (ETF) industry saw one of its largest monthly gains in November, with data compiled by ETF.com showing that U.S.-listed ETFs witnessed $42 billion in net inflows for the month. [1] The strong performance for the extremely popular investment channel helped asset managers rake in more than $192 billion in net new money across their ETF offerings for the eleven-month period this year – comfortably surpassing the $188 billion record figure for full-year 2013. U.S.-listed ETFs are just shy of $2 trillion in total assets – a threshold they are very likely to cross by the end of the year thanks to the record run for the equity market over recent weeks.
    ,BlackRock (NYSE:BLK) gained the most over the year, with the financial institution capitalizing on its position as the world’s largest asset manager as well as world’s largest ETF provider to report net inflows of $71.4 billion in the U.S. and almost $90 billion worldwide. [2] Vanguard, which saw an exceptionally strong start to the year (see Vanguard Trumps BlackRock, State Street To Record Highest ETF Inflows In Q1), comes in a close second with $63.5 billion in U.S. inflows and $75 billion in global inflows. This has brought Vanguard within striking distance of State Street (NYSE:STT) for the position of the second largest U.S.-listed ETF provider.
    Regards,
    Ted
    http://www.trefis.com/stock/blk/articles/271067/blackrock-continues-to-make-the-most-of-the-etf-growth-story/2014-12-19
  • Inflation and the value of the $
    @Tampabay
    How is a U.S. president (regardless of party affiliation) directly responsible for a large increase in inflation? Albeit, the two most recent (and ongoing) wars have caused vast sums of debt.
    Cost of Iraq/Afgan Wars, one source, March, 2013
    Thanks.
    Catch
  • Barry Ritholtz: No Room For Feelings In The Market
    Problem: 24/7 financial news cycle, Solution: you must learn to filter garbage, take ONLY what YOU can use (to make money), file the rest into useless, then make your OWN decisions
    Predictions: are for entertainment purposes only, have fun with them, do your own:
    I predict we will make good money in 2014,esp. after 2013, and we will make money again in 2015, write that one down for your first 2015
  • Barry Ritholtz: No Room For Feelings In The Market
    LATEST MEMO FROM OUR CHAIRMAN, HOWARD MARKS
    Memo to: Oaktree Clients
    From: Howard Marks
    Re: The Lessons of Oil December 20,2014 © 2007-2014 Oaktree Capital Management, L.P. All Rights Reserved.(excerpts)
    "Over the last year or so, while continuing to feel that U.S. economic growth will be slow and unsteady in the next year or two,
    I came to the conclusion that any surprises
    we're most likely to be to the upside. And my best candidate for a favorable development has been the possibility that the U.S. would sharply increase its production of oil and gas. This would make the U.S. oil-independent, making it a net exporter of oil and giving it a cost advantage in energy–based oncheap production from fracking and shale–
    and thus a cost advantage in manufacturing. Now the availability of cheap oil all around the world threatens those advantages. So much for macro
    forecasting!

    There’s a great deal to be said about the price change itself.
    A well-known quote from economist
    Rudiger Dornbusch goes as follows:
    “In economics things take longer to happen than you
    think they will, and then they happen faster than you thought they could.”
    I don’t know if
    many people were thinking about whether the price of oil would change, but the decline of 40%-plus must have happened much faster than anyone thought possible.
    On the other hand
    –and in investing there’s always another hand–high levels of confidence,
    complacency and composure on the part of investors have in good measure given way to disarray and doubt, making many markets much more to our liking
    .
    For the last few years, interest rates on the safest securities–
    brought low by central banks
    –have been coercing investors to move out the risk
    curve. Sometimes they’ve made that journey without cognizance of the risks they were taking, and without thoroughly understanding the investments they undertook. Now they
    find themselves questioning
    many of their actions, and it feels like risk tolerance is being replaced by risk aversion.
    This paragraph describes a process through which investors are made to feel pain, but also one that makes markets much safer and potentially more bargain-laden.
    http://www.oaktreecapital.com/MemoTree/The Lessons of Oil.pdf
    Elsewhere; A look at the commodity bubble in the 2000-08 period.Just an observance of the past for me personally.I have no opinion on his bullish outlook for oil. Article from Seeking Alpha.
    Lawrence Fuller, Fuller Asset Management Dec. 20, 2014 2:55 PM ET
    The Oil Price Plunge - Fiction, Reality And Opportunity (excerpts)
    "Shortly after the tech bubble burst in 2000, institutions began to allocate billions of dollars into commodities through the futures markets in an effort to capitalize on growth in the developing world. Commodities became a new financial asset class. The continual and escalating flow of funds into a buy-and-hold strategy of a basket of commodities with no sensitivity to price led to a parabolic move upwards in prices prior to the financial crisis in 2008.
    The regulatory body for the futures exchanges (CFTC) exacerbated the volatility by exempting Wall Street banks from the limits under which traditional speculators operate. As a result, a hedge fund can use a Wall Street bank as a counter-party to speculate on commodity prices for financial gain with no limitations. It is important to recognize that the vast majority of oil futures contract holders never take delivery of a single barrel of oil-they simply roll over the contracts. As a result of these changes in market structure, futures prices now dictate spot prices.
    There was no greater evidence of commodity prices divorcing from fundamentals than the surge in oil to $147/barrel during the summer of 2008. That parabolic move occurred six months into what we now call the Great Recession. There were no lines at the gas pump. There was no outcry from oil-importing nations that they were unable to obtain the oil that they needed. That move was fueled by speculative investment flows into oil futures contracts in a herd mentality. The herd was being steered (over a cliff) in part by deluded research reports from Morgan Stanley and Goldman Sachs that were forecasting prices of $150 and $200/barrel, respectfully. Just a few months later the price had collapsed to less than $60/barrel, but not because of a commensurate decline in demand or increase in supply. Institutional investors and speculators were being forced to deleverage and unwind long positions in the throes of the financial crisis and stock market meltdown"
    http://seekingalpha.com/article/2770205-the-oil-price-plunge-fiction-reality-and-opportunity?ifp=0
  • Target-Date Funds: Twice As Popular Vs. 15 Years Ago
    FYI: Many workers want to put their retirement accounts on autopilot.
    That's the lesson from new data that show that recently hired plan members flock to balanced funds — which include target-date funds
    Regards,
    Ted
    http://license.icopyright.net/user/viewFreeUse.act?fuid=MTg3NzE2ODQ=
    Enlarged Graphic: http://news.investors.com/photopopup.aspx?path=webMFbalanc122214.png&docId=731592&xmpSource=&width=1000&height=562&caption=&id=731583
  • 5 Great Tech Funds Without Loads
    FYI: Add spice to your portfolio with these top-performing no-load mutual funds that focus on technology stocks.
    Regards,
    Ted
    http://www.kiplinger.com/printstory.php?pid=13111